Business Wire

Diversified NANO Solutions Corp. Introduces Revolutionary Biologically Encrypted Digital Inks at Graph Expo 2016, September 25-28, 2016 in Orlando, FL


Diversified NANO Solutions Corporation (DNSC), will be exhibiting Digital Inks and special effect solutions for inkjet print systems by Canon (NYSE: CAJ), Ricoh, Hewlett Packard (NYSE: HPQ), Epson, Xerox (NYSE: XRX), Konica Minolta, Screen, Kyocera, Brother, Pitney Bowes (NYSE: PBI) and more at Graph Expo 2016 – September 25-28, at Orange County Convention Center – North, Orlando, Florida, Booth #2838.

DNSC is proud to introduce revolutionary INKcrypt® identity ink-trace technology, based on advanced biological encryption to provide counterfeit elimination, highly sophisticated protection of brands, supply chain integrity, and authentication of physical items, documents and printed content broadly. Businesses, institutions and users now have the ability to uniquely transfer a permanent biologically encrypted identity to documents, tickets, tags, labels, materials, branded products, IDs/badges, checks and virtually any printed output by using INKcrypt® Ink with built-in biological identity tracers. Unlike conventional anti-counterfeiting and tracking methods, adoption of INKcrypt® provides ultimate reliability and protection without requiring any changes to an existing print workflow. No additional print passes, non-standard procedures and/or verification steps! The unique biologically encrypted identity is transferred with the same ink which is used for printing the print job. On-the-spot authentication is performed with INKcrypt® Qtouch™, an instant test for positive INKcrypt® Ink identification. INKcrypt® is eco-friendly, harmless to human health (FDA compliant) and compatible with the entire portfolio of x-nano™ Digital Inks suitable for dot-on-demand inkjet systems, offset, flexo, gravure and hand-held writing instruments. In addition to instant physical INKcrypt® Ink verification, the system is backed by an online validation platform to authenticate Qtouch™ test devices and matching INKcrypt® Ink, anytime, anywhere! INKcrypt® Ink and Qtouch™ test devices are available to validated subscribers worldwide.

Based in San Diego, California, with manufacturing facilities in the US and Europe, DNSC specializes in developing and manufacturing Digital Inks, nano materials and fluids for high-resolution, high-performance digital inkjet printing. DNSC provides unique ink development services, research and turnkey ink supply and fulfillment solutions reaching end users, resellers and printer manufacturers worldwide. DNSC has developed an extensive product line under the x-nano™ brand, providing a range of solutions including high-quality, low-cost value black & color dye inks (V-Series), elite pigment inks (E-Series), special ultra-fast-dry-inks (S-Series), magnetic MICR inks (K-Series), invisible fluorescent color (RGB) inks, infrared-absorbing inks (I-Series), and special inks for food grade, textile and special effect applications (F-, T-, and X-Series). The company’s Digital Inks target dot-on-demand inkjet applications based on thermal and piezo print heads using aqueous, oil, energy curable (UV/LED) and eco-solvent based inks.

DNSC offers a wide array of inkjet inks supporting direct mail, transactional, transpromo, books, catalogs/magazines, ticket, tags, labels and graphics printing applications. DNSC is uniquely positioned to help users create differentiated, high-value output through personalization using x-nano™ special effect inks such as magnetic (MICR), invisible fluorescent, spot color and security inks for thermal & piezo digital inkjet platforms.

The company supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and applications. These include specialty substrates, UV display lights, INKVERSE™ Infinite Ink Infuser — a revolutionary and cost-effective way to adopt and deliver Digital Inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome™ — an invisible color image generator software to transform CMYK into UV fluorescent RGB output, and more.

New to Graph Expo 2016, is DNSC X-Series, a new family of pigment powders and dispersions to serve as base components for custom development and production of ink, paint, paste, dispersion, gel, cream and powder. These special effect base materials photo-luminesce, fluoresce, absorb IR, and change color with light or heat. X-Series materials have highly customizable properties that allow for various exceptionally unique market applications associated with digital and non-digital printing applications. Also new are food grade and textile pigment powders, both available in a large variety of colors that are ideal for ink (digital, offset, flexo), paint, paste dispersions, gel and powder components ideal for custom food and textile market applications.

DNSC will be showcasing revolutionary INKcrypt® identity ink-trace technology, its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space. Here you can learn about X-Base Global™, DNSC’s new ink manufacturing license program for high-performance on-demand Digital Inks to enhance quality and shelf life, to save on inventory and product costs. Quick-start with X-Base dispersions and standard off-the-shelf DNSC X-Base cofactor solutions, or develop and use your own suitable ink solvent add-ins, to fast track your ink production.

Visit Team DNSC at Booth #2838 and discover DNSC “digital INKS unlimited!"

Contact information

Diversified NANO Solutions Corporation
Robert von Bujtar
US: +1.858.924.1005
EU: +41.41 874 08 50

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on